MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
906.54
-0.78
-0.09%
After Hours: 906.54 0 0.00% 16:43 04/24 EDT
OPEN
906.90
PREV CLOSE
907.32
HIGH
915.70
LOW
904.41
VOLUME
373.72K
TURNOVER
0
52 WEEK HIGH
998.33
52 WEEK LOW
684.81
MARKET CAP
99.50B
P/E (TTM)
26.07
1D
5D
1M
3M
1Y
5Y
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
NASDAQ · 16h ago
Regeneron Pharma Is Maintained at Buy by TD Cowen
Dow Jones · 18h ago
Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Kiniksa Pharmaceuticals reported strong Q1 2024 results, with net sales of Arcalyst growing 85% YoY and 11% sequentially. Arcalyst's strong performance has driven a $10 million increase in the full-year net sales guidance range. The company plans to develop abiprubart for the treatment of Sjogren's syndrome. The upside in the next 2-3 years depends on Arcalyst.
Seeking Alpha · 18h ago
Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo. 17 presentations to highlight Regeneron's investigational pipeline at the American Society of Clinical Oncology 2024 Annual Meeting. New and updated data from its oncology and hematology pipeline will be shared across 17 presentations.
Benzinga · 22h ago
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
NASDAQ · 23h ago
REGENERON PHARMACEUTICALS INC <REGN.O>: TD COWEN RAISES TARGET PRICE TO $1,030 FROM $1,020
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-Airbnb, American Express, Mattel
Wall Street analysts revise their ratings and price targets on several U.S. Listed companies. American Express Co, Mattel and Amazon.com among those revised. Analysts raise target prices for American Express, Amazon, Fiserv and other companies. Airbnb, American Express and Mattel raise to buy from Mizuho.
Reuters · 1d ago
UPDATE 2-Roche eyes return to growth after Q1 hit by forex, loss of COVID sales
Roche eyes return to growth after Q1 hit by forex, loss of COVID sales, strong Swiss franc. First-quarter sales fell by 6% to 14.4 billion Swiss francs, in line with expectations. Swiss drugmaker sees continued boost from eye drug Vabysmo. Reiterates 2024 guidance of sales growth in "mid single-digit" percentage range.
Reuters · 1d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.